SEER-Medicare analyses across 2005–2007, 2010–2012, and 2017–2019 showed persistently lower adjusted curative-treatment rates ...
Clinical outcomes of tepotinib and immune checkpoint inhibitor therapy for MET exon 14 skipping NSCLC: A multicentric retrospective analysis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
The KRAS p.G12D variant occurs in 5% of patients with non–small-cell lung cancer (NSCLC) and is the most common substitution variant in pancreatic ductal adenocarcinoma, occurring in 40% of ...
Week-18 ORR equivalence was achieved for HD204 vs reference bevacizumab (48.7% vs 46.5%), with both risk ratio and risk ...
This episode, titled Optimizing Subcutaneous Therapies in NSCLC: Practical Integration, Patient Selection, and Workflow ...
Watch out, Johnson & Johnson. Dizal has reported positive phase 3 results for its oral Zegfrovy that could put more pressure ...
According to a bridging analysis, two PD-L1 immunohistochemical assays — Dako 22C3 and VENTANA SP263 — demonstrated 88% concordance in identifying patients with non-small cell lung cancer (NSCLC) for ...
Bispecific antibodies have ushered in a transformative era in treating non–small cell lung cancer (NSCLC), enabling dual-pathway targeting with promising clinical outcomes in previously refractory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results